TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30948276
Drug: RB-CHOP (Rituximab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RB-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone + Bortezomib 1.3 mg/m2 intravenously or 1.6 mg/m2 subcutaneously on days 1 and 8 for cycles two to six)
Study: 25127655
Drug: Reduced-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose warfarin for 3-6 days aiming for INR < 1.7
Study: 25127655
Drug: Interrupted warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interrupted warfarin for 5 days with LMWH bridging for 2.5 days
Study: 22622649
Drug: Levosimendan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.1 μg/kg/min for 24 hours)
Study: 22622649
Drug: Milrinone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (0.5 μg/kg/min for 24 hours)
Study: 19922961
Drug: RSG (rosiglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSG (rosiglitazone 8 mg/d)
Study: 19922961
Drug: RSG +
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RSG + EX (rosiglitazone 8 mg/d plus exercise training)
Study: 17672962
Drug: Yunnan Baiyao
Normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yunnan Baiyao (500 mg four times daily for 3 days before surgery)
Study: 15615872
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate (140 mg/day; n=26)
Study: 9698950
Drug: hyperbaric lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hyperbaric lidocaine 50 mg/ml diluted with CSF 1:1 (Group L)
Study: 9698950
Drug: hyperbaric mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperbaric mepivacaine 40 mg/ml (Group M)
Study: 9698950
Drug: hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperbaric bupivacaine 5 mg/ml (Group B)
Study: 8681269
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy using a fluorescent light box (2500 lux for 2 hours per day)
Study: 8681269
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy using a fluorescent light box (10,000 lux for 30 minutes)
Study: 158570
Drug: tretinoin lotion
Normalized name: tretinoin Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: tretinoin lotion 0.05% applied in the morning and benzoyl peroxide 5% and 10% applied at night
Study: 28463827
Drug: Taurolidine lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolidine lock solution
Study: 28463827
Drug: Standard saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard saline solution (Control)
Study: 9990415
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% cream
Study: 19958063
Drug: Educational outreach
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational outreach visits for reducing selected antibiotics (14 practices)
Study: 19958063
Drug: Educational outreach
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational outreach visits for improving antidepressant prescribing (14 practices)
Study: 17944686
Drug: lopinavir/saquinavir/ritonavir (LPV/SQV/r;
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/saquinavir/ritonavir (LPV/SQV/r; 400/1000/100 mg bid)
Study: 17944686
Drug: indinavir/ritonavir (IDV/r;
Approvals — FDA: no, EMA: no, PMDA: no
Description: indinavir/ritonavir (IDV/r; 800/100 mg bid) plus two NRTIs
Study: 15356029
Drug: Metformin (425
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (425 mg/d) for 6 months in prepubertal girls
Study: 15356029
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg/d) for 12 months in postpubertal girls
Study: 8331334
Drug: Placebo Treatment
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Treatment
Study: 8323306
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (bacitracin plus Band‐Aid)
Study: 28700805
Drug: Lisdexamfetamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisdexamfetamine (50 or 70 mg)
Study: 16473558
Drug: Extended-release divalproex
Normalized name: divalproex sodium Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release divalproex sodium (divalproex-ER) every 12 hours (q12h)
Study: 16473558
Drug: Once-daily divalproex-ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily divalproex-ER
Study: 10885442
Drug: Hypericum oil
Normalized name: Hypericum oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum oil (hypericin 110 microg/mL)
Study: 10885442
Drug: Hypericum ointment
Normalized name: Hypericum oil
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum ointment (hypericin 30 microg/mL)
Study: 1468386
Drug: Morphine (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (group M) - 50 micrograms/kg per h, increased to 100 micrograms/kg per h if needed
Study: 1468386
Drug: Morphine with
Normalized name: opium alkaloids with morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine with Pancuronium (group M+P)
Study: 6331136
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg purified brain gangliosides for six months
Study: 30976851
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg/day, n=12, MET group)
Study: 30976851
Drug: Metformin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2000 mg/day, n=12, CONT group)
Study: 25033565
Drug: Tianeptine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (administered for three days)
Study: 25033565
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline (administered for three days)
Study: 25033565
Drug: Imipramine (sub-chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (sub-chronic administration for 6 days)
Study: 20417447
Drug: atorvastatin 80mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 80mg
Study: 16152757
Drug: IFN-alpha 3
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha 3 MIU subcutaneously three times a week plus 100 mg MMPD (every 8 h) for 4 weeks
Study: 16152757
Drug: IFN-alpha 3
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha 3 MIU subcutaneously three times a week plus 300 mg MMPD (every 8 h) for 4 weeks
Study: 11966932
Drug: Amoxycillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (250 mg) and Metronidazole (200 mg) (AM)
Study: 11966932
Drug: Lactate capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate capsules and Metronidazole (PM)
Study: 11966932
Drug: Amoxycillin and
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin and Calcium Lactate tablets (AP)
Study: 10424912
Drug: Vigorous oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigorous oral hydration (20 mL/kg)
Study: 1602947
Drug: High potency
Normalized name: High Potency B+C
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High potency multivitamin-mineral supplement
Study: 26670986
Drug: Daily changing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily changing load (DCL)
Study: 21697819
Drug: Functional yogurt
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional yogurt NY-YP901 (150 ml, twice a day for 8 weeks)
Study: 21697819
Drug: Placebo yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo yogurt (twice a day for 8 weeks)
Study: 16889444
Drug: Olanzapine/fluoxetine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine/fluoxetine combination (OFC) 6/25, 6/50, 12/25, or 12/50 mg/day
Study: 16889444
Drug: Lamotrigine titrated
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine titrated to 200 mg/day
Study: 14748761
Drug: Control (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (other chemotherapeutic agents)
Study: 11251135
Drug: Preemptive multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive multimodal analgesia (IV ketorolac 30 mg, intra-articular ropivacaine 0.25% + morphine 2 mg + epinephrine 1:200,000, femoral nerve block with ropivacaine 0.25%) administered 15 minutes before skin incision
Study: 11251135
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (multimodal analgesia administered immediately after skin closure)
Study: 1606393
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (1.2 U/kg/week)
Study: 29454501
Drug: Nutricia preOp®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutricia preOp® (800 ml on the night before surgery/400 ml 2-3 h preoperatively)
Study: 29454501
Drug: Placebo (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (800 ml on the night before surgery/400 ml 2-3 h preoperatively)
Study: 22657252
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate oral powder (1000 mg, 3000 mg/d for 10 doses)
Study: 22657252
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate chewable tablet (1000 mg, 3000 mg/d for 10 doses)
Study: 22657252
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (oral powder and chewable tablet)
Study: 18849849
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (AP)
Study: 18849849
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (NP)
Study: 11817468
Drug: 15% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% carbamide peroxide bleaching agent with reservoirs
Study: 11817468
Drug: 15% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% carbamide peroxide bleaching agent without reservoirs
Study: 10072242
Drug: Adjusted-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose warfarin therapy (international normalized ratio 2.0 to 3.0)
Study: 8590744
Drug: Thrombolytic or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic or angioplasty therapy
Study: 2405738
Drug: Preanesthetic medication
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preanesthetic medication
Study: 2405738
Drug: No preanesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preanesthetic medication
Study: 511251
Drug: Formolized KFD
Normalized name: Formol
DrugBank: Formaldehyde (DB03843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formolized KFD virus vaccine (two doses administered to 1405 individuals)
Study: 511251
Drug: Formolized KFD
Normalized name: Formol
DrugBank: Formaldehyde (DB03843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formolized KFD virus vaccine
Study: 28107853
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intervention, usual daily activities)
Study: 26051567
Drug: Inhalation aromatherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation aromatherapy with 2% lavender essential oil for 20 min
Study: 24016218
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 fortified food (1.4 μg/day)
Study: 21235333
Drug: Systemic antimicrobials
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antimicrobials (500 mg amoxicillin + 250 mg metronidazole; three times a day for 10 days)
Study: 19660681
Drug: CNS prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS prophylaxis during initial treatment for aggressive NHL
Study: 31988972
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg once daily
Study: 8790569
Drug: Interferon-alpha 2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha 2a (2.5 MIU m-2, 5.0 MIU m-2, 10.0 MIU m-2) three times weekly by intramuscular injection for 12-24 weeks
Study: 30503831
Drug: Short-term intensive
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term intensive insulin therapy (IIT) consisting of basal detemir and premeal insulin aspart
Study: 25395350
Drug: 75 g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g oral glucose
Study: 25395350
Drug: 100 g standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g standard noodle
Study: 23664707
Drug: HAA (homoharringtonine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAA (homoharringtonine 2 mg/m² per day on days 1-7, cytarabine 100 mg/m² per day on days 1-7, and aclarubicin 20 mg/day on days 1-7)
Study: 23664707
Drug: HAD (homoharringtonine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAD (homoharringtonine 2 mg/m² per day on days 1-7, cytarabine 100 mg/m² per day on days 1-7, and daunorubicin 40 mg/m² per day on days 1-3)
Study: 23664707
Drug: DA (daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA (daunorubicin 40-45 mg/m² per day on days 1-3 and cytarabine 100 mg/m² per day on days 1-7)
Study: 10498385
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Aspirin
Study: 10498385
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Pycnogenol
Study: 10498385
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg Pycnogenol
Study: 10498385
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Pycnogenol
Study: 8698504
Drug: Hexavalent PorA
Normalized name: PORACTANT ALFA
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hexavalent PorA outer membrane vesicle vaccine (50 or 100 micrograms)
Study: 8698504
Drug: Hexavalent PorA
Normalized name: PORACTANT ALFA
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hexavalent PorA outer membrane vesicle vaccine
Study: 2069220
Drug: Bacteriostatic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteriostatic saline flush solution
Study: 2069220
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline flush solution
Study: 6897123
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg atropine intravenously
Study: 6897123
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pirenzepine intravenously
Study: 6897123
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg pirenzepine perorally twice daily for 4 days
Study: 6897123
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg L-hyoscyamine perorally twice daily for 4 days
Study: 22631626
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral midazolam (0.5 mg/kg) and ketamine (3 mg/kg) (MK)
Study: 22631626
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (1.0 mg/kg) (MS)
Study: 22631626
Drug: No sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sedative (PS)
Study: 11692987
Drug: Metamizol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol (1 g intramuscular every 8 hours)
Study: 11692987
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg intramuscular every 12 hours)
Study: 8434332
Drug: placebo-control treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo-control treatment
Study: 3303918
Drug: alpha 2-interferon
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alpha 2-interferon as an intranasal spray
Study: 29630112
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (external radiation, systemic chemotherapy or conservative treatment)
Study: 17595451
Drug: Euthyrox (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euthyrox (50 mkg daily) after PEI
Study: 3064774
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic treatment (0)
Study: 27905916
Drug: 100 to
Normalized name: Zionodil 100 Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 to 250 mg lisdexamfetamine, dispensed daily on site, over an 8-week period
Study: 25124303
Drug: Cocaine self-administration
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine self-administration
Study: 20707210
Drug: Songling Xuemaikang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Songling Xuemaikang + Shuxuetong + Aspirin enterie coated tablets
Study: 20707210
Drug: Shuxuetong +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxuetong + Aspirin enterie coated tablets
Study: 11835076
Drug: HCTZ plus
Normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ plus perindopril 2 mg
Study: 11835076
Drug: HCTZ plus
Normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ plus perindopril 4 mg
Study: 11835076
Drug: HCTZ plus
Normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ plus perindopril 8 mg
Study: 3284266
Drug: Peroral opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral opioid therapy (SO)
Study: 3284266
Drug: Epidural catheter
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural catheter connected to an implanted injection port (Port)
Study: 30079329
Drug: L‐ornithine L‐aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐ornithine L‐aspartate
Study: 27386641
Drug: Telbivudine Tablet
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telbivudine Tablet (600 mg, once per day) combined with Jianpi Bushen Recipe (twice per day)
Study: 27386641
Drug: Telbivudine Tablet
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telbivudine Tablet alone
Study: 24607797
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg misoprostol vaginally 6 hours before HSG
Study: 24607797
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac potassium orally 45 to 60 minutes before HSG
Study: 20394870
Drug: Omega-3 ethyl
Normalized name: Cyanocobalamin/Omega-3 Fatty Acids/Pyridoxine 6 MCG-725 MG-8 MG Oral Capsule, Liquid Filled [VITAMIN B PLUS+ OMEGA-3 ETHYL ESTER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 ethyl esters (1 g/day)
Study: 389827
Drug: Bacampicillin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin (800 mg t.i.d. for 10 days)
Study: 389827
Drug: Pivampicillin (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin (700 mg t.i.d. for 10 days)
Study: 28945060
Drug: Micronized purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized purified flavonoid fraction (MPFF) 1000 mg daily for 2 weeks before and for at least 2 months after sclerotherapy
Study: 24305085
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with immediate feedback for each session
Study: 24305085
Drug: Treatment without
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment without feedback
Study: 18199015
Drug: Guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery therapy (listening to a 25-minute guided imagery CD twice a day for 8 weeks)
Study: 18199015
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (resting for 25 minutes twice daily for 8 weeks)
Study: 10440419
Drug: Clopidogrel 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 50 mg
Study: 10440419
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg (multiple doses for 14 days)
Study: 10440419
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg (long-term study for 12 weeks)
Study: 27010625
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab administered monthly
Study: 27010625
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab administered as needed (PRN)
Study: 27010625
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg ranibizumab administered monthly
Study: 27010625
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg ranibizumab administered as needed (PRN)
Study: 27010625
Drug: PRN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN treatment
Study: 25439809
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (67 μg/kg/day) for 1 year followed by 2 years of randomized GH treatment (67 μg/kg/day, 35 μg/kg/day, or IGF‐I titrated)
Study: 18284652
Drug: Lactulose (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (10 g b.d.)